KRAS and lung adenocarcinoma: It would also be of interest to see whether these findings extend to other KRAS mutants such as KRASG12C, which can also be targeted to produce an antitumor immune response [15], or to other KRAS‐mutated cancer contexts such as lung adenocarcinoma.